John is the Head of Corporate Development. He has over 38 years of broad commercialization experience within the biopharmaceutical industry. Most recently, John advised contract research organization Vanguard Clinical, Relmada Therapeutics, and several CNS focused pharma companies. He is a co-founder in Gate Neurosciences and established Salt Creek Biosciences, a new product planning consulting company. Much of his experience came from his 31-year career with Eli Lilly and Company. Prior to retiring from Lilly, John was Senior Director for Global New Product Planning – Biomedicines where he and his team worked side-by-side with discovery and early phase development scientists and physicians to assess the probability of commercial success of early phase assets in neurodegeneration, psychiatry, pain, migraine, immunology, and other therapeutic areas.

Before that, John held numerous marketing leadership roles with Lilly in the United States, Spain, South Korea, and Australia. He was the U.S. brand and launch leader of Cymbalta (duloxetine) for both major depressive disorder and diabetic peripheral neuropathic pain. John received a bachelor’s degree in economics from DePauw University and an MBA from the University of Miami (Coral Gables, Florida).